Objectives To compare the costs and effectiveness of dabigatran etexilate with current
standard treatment in patients with non-valvular atrial fibrillation (NVAF), from the Slovakian …

Objectives To estimate the cost-effectiveness of Dabigatran etexilate 150dib relative to
Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treatment, in the …

Objectives Patients with atrial fibrillation (AF) are at increased risk of stroke. Furthermore, AF-
related strokes are associated with greater severity, disability, and mortality than strokes of …

Objectives To investigate the cost-effectiveness of dabigatran etexilate (dabigatran 150MG)
in the Turkish health care setting. Methods A model was constructed to assess the cost …

Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …

Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …

Objectives After decades of warfarin as the dominant strategy for stroke prevention in atrial
fibrillation (SPAF), new treatments are available. These include new pharmaceuticals like …

Objectives In the management of atrial fibrillation (AF), warfarin has been the anticoagulant
of choice for preventing thrombotic complications, however, its need for regular blood test …

Objectives Analysis of cost containment of SSI via use of Dabigatran Etexilate (150MG)
versus current standard of care (Warfarin) in prevention of stroke for non valvular atrial …

Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …